Landmark trials, including CREDENCE, DAPA-CKD, EMPA-KIDNEY, and FLOW, have demonstrated their efficacy in preserving kidney function and reducing adverse outcomes
PubMedPMC 57
Retatrutide is a novel triple-agonist peptide developed by Eli Lilly, targeting GIP, GLP-1, and glucagon receptors, showing significant promise in clinical trials for obesity and type 2 diabetes due to its potent effects on appetite, energy expenditure, and glycemic control
We currently offer virtual appointments for clients located in Arizona, California, Colorado, Washington State, Nevada, Oregon, and Texas
These can include severe gastrointestinal problems like nausea or vomiting, and in rare cases, pancreatitis
Until now the tests with exendin-4 had only been done in mice and the company was unsure what would happen when it was given to humans